alpha-chymotrypsin and Bernard-Soulier-Syndrome

alpha-chymotrypsin has been researched along with Bernard-Soulier-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for alpha-chymotrypsin and Bernard-Soulier-Syndrome

ArticleYear
Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.
    The Journal of clinical investigation, 1987, Volume: 79, Issue:6

    We previously identified a 210,000-mol-wt platelet glycoprotein (GP 210) that is missing from Bernard-Soulier platelets, and found that an antibody against GP 210 inhibits ristocetin-induced platelet agglutination. We now show by immunoblotting that GP 210 binds heat-aggregated rabbit and human IgG, as well as keyhole limpet hemocyanin (KLH)-anti-KLH and ovalbumin (OA)-anti-OA immune complexes. Immune complex binding to GP 210 was preserved on chymotrypsin-treated platelets that lacked glycoprotein Ib (GP Ib). In contrast, ristocetin-induced platelet agglutination resulted in disappearance of immunologically detectable GP 210 and loss of immune complex binding, even though GP Ib remained intact. Purified Fc fragments inhibited binding of anti-GP 210 antibody to intact platelets and to GP 210 on immunoblots. The Fc fragments also blocked immune complex binding to GP 210. Conversely, anti-GP 210 antiserum and F(ab)2 fragments inhibited binding of fluorescein-labeled Fc fragments to intact platelets. We conclude that GP 210 functions as a platelet Fc receptor.

    Topics: Antibodies; Antigen-Antibody Complex; Bernard-Soulier Syndrome; Blood Platelets; Chymotrypsin; Detergents; Humans; Molecular Weight; Platelet Membrane Glycoproteins; Receptors, Fc; Ristocetin

1987